Targeting TNFR2 for Cancer Immunotherapy & Beyond

10:00 am - Thursday 25th March 2027

  • Antibodies to TNFR2 employ different modes of actions to trigger antitumor immunity
  • Ligand-blocking a TNFR2 turns cold tumors hot by a differentiated mechanism involving Treg depletion, myeloid reprogramming, and induction of CD8+ T-cells, stimulating tertiary lymphoid structure formation
  • Agonist antibodies expand and activate CD4+ and CD8+ T-cells and NK-cells, activating a broad IFN response, indicating potential in vaccine and cell therapy, and the implications for design of TNFR2 agonist antibodies for I&I

Speakers:

Chief Scientific Officer
BioInvent